Dark

ARVN
Arvinas, Inc
stock NASDAQ

At Close

Jul 3, 2025 12:59:59 PM EDT

7.95USD+0.570%(+0.05)826,658

0.00Bid 0.00Ask 0.00Spread

Pre-market

Jul 3, 2025 9:01:30 AM EDT

7.96USD+0.759%(+0.06)630

After-hours

Jul 2, 2025 4:00:30 PM EDT

7.90USD-0.126%(-0.01)0

OverviewOptionsHistoricalExchangesShortsNews

Jan 19, 2022

10:02AM EST Benzinga's Top Ratings Upgrades, Downgrades For January 19, 2022 Benzinga

05:38AM EST Goldman Sachs Initiates Coverage On Arvinas with Buy Rating, Announces Price Target of $157 Benzinga

Dec 10, 2021

10:40AM EST Arvinas, Pfizer's ARV-471 Shows Clinical Benefit Rate Of 40% In Pretreated Breast Cancer Patients Benzinga

08:12AM EST Pfizer, Arvinas Report PROTAC Protein Degrader ARV-471 Continues To Show Clinical Benefit Rate In Patients With Locally Advanced, Metastatic ER-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Benzinga

08:10AM EST ARV-471 continues to show a favorable tolerability profile and robust ER degradation in updated phase 1 dose escalation data presented at San Antonio Breast Cancer Symposium GlobeNewswire Inc

07:50AM EST The Daily Biotech Pulse: Lilly Sings Metabolic Disorder Drug Pact, Moderna Reports Positive Flu Vaccine Data, Halozyme To Buy Back Shares Benzinga

Dec 7, 2021

10:03AM EST Benzinga's Top Ratings Upgrades, Downgrades For December 7, 2021 Benzinga

04:56AM EST Cowen & Co. Initiates Coverage On Arvinas with Outperform Rating Benzinga

Dec 6, 2021

06:07AM EST The Week Ahead In Biotech (Dec. 6-Dec. 11): Dar FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More Benzinga

Nov 19, 2021

09:56AM EST Arvinas And Pfizer Announce Updated Phase 1 Dose Escalation Data For ARV-471 To Be Presented In Spotlight Poster Session At 2021 San Antonio Breast Cancer Symposium Dec. 10 Benzinga

09:55AM EST Arvinas and Pfizer Announce Updated Phase 1 Dose Escalation Data GlobeNewswire Inc

Nov 10, 2021

07:00AM EST Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Sean Cassidy, Chief Financial Officer, and Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on Tuesday, November 16 at 10:40 a.m. ET. GlobeNewswire Inc

Nov 3, 2021

09:15AM EDT Arvinas Q3 EPS $(0.94) Down From $(0.79) YoY, Sales $9.28M Up From $7.60M YoY Benzinga

07:00AM EDT Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update. GlobeNewswire Inc

Oct 20, 2021

04:02PM EDT Neurona Therapeutics Appoints Brad Margus to its Board of Directors GlobeNewswire Inc

Oct 14, 2021

12:30PM EDT Analyst Ratings For Arvinas Benzinga

11:18AM EDT Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2021 Benzinga

07:40AM EDT SVB Leerink Initiates Coverage On Arvinas with Outperform Rating, Announces Price Target of $115 Benzinga

Sep 30, 2021

12:08PM EDT Expert Ratings For Arvinas Benzinga

11:04AM EDT Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021 Benzinga

04:56AM EDT Stifel Initiates Coverage On Arvinas with Buy Rating, Announces Price Target of $115 Benzinga

Sep 9, 2021

01:18PM EDT Analyst Ratings For Arvinas Benzinga

11:05AM EDT Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2021 Benzinga

07:10AM EDT B of A Securities Initiates Coverage On Arvinas with Buy Rating, Announces Price Target of $110 Benzinga

Sep 1, 2021

07:00AM EDT Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it will participate in two upcoming virtual investor conferences: GlobeNewswire Inc

Aug 9, 2021

11:36AM EDT Roth Capital Maintains Buy on Arvinas, Raises Price Target to $135 Benzinga

09:20AM EDT Arvinas And Insilico Medicine Announce R&D Collaboration Benzinga

09:17AM EDT Insilico Medicine Announces an AI-driven PROTAC R&D Collaboration with Arvinas PR Newswire

Aug 5, 2021

07:39AM EDT Arvinas Q2 EPS $(1.03) Down From $(0.65) YoY, Sales $5.54M Down From $5.75M YoY Benzinga

07:00AM EDT Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update. GlobeNewswire Inc

Jul 30, 2021

07:54AM EDT The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs Benzinga

Jul 29, 2021

08:18AM EDT The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs Benzinga

Jul 27, 2021

11:13AM EDT The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts Benzinga

Jul 23, 2021

10:51AM EDT UPDATE: Roth On Arvinas: Firm Highlights $2B Collaboration With Pfizer For ARV-471 Estrogen Receptor Degrader In Breast Cancer With Co. Receiving $650M Upfront, $400M Upon Approval & Up To $1B For Commercial Milestones; Selects Co. As 2H2021 Top Pick Benzinga

10:50AM EDT Roth Capital Maintains Buy Rating On Arvinas Inc With $120 Price Target Benzinga

07:59AM EDT 10 Biggest Price Target Changes For Friday Benzinga

06:43AM EDT Citigroup Maintains Buy on Arvinas, Raises Price Target to $153 Benzinga

06:32AM EDT Oppenheimer Maintains Outperform on Arvinas, Raises Price Target to $108 Benzinga

Jul 22, 2021

03:42PM EDT Arvinas Option Alert: Aug 20 $110 Calls at the Ask: 1000 @ $2.65 vs 2 OI; Earnings 8/3 Before Open [est] Ref=$84.04 Benzinga

11:34AM EDT The Daily Biotech Pulse: FDA Nod For Merck-Eisai, Seres' Ulcerative Colitis Drug Flunks Midstage Study, Pfizer To Invest In Arvinas, Absci IPO Benzinga

10:21AM EDT Truist Securities Maintains Buy on Arvinas, Raises Price Target to $170 Benzinga

08:38AM EDT Pfizer Inc. (PFE) and Arvinas, Inc. (ARVN) announced Thursday a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. RTTNews

08:18AM EDT The Daily Biotech Pulse: FDA Nod For Merck-Eisai, Seres' Ulcerative Colitis Drug Flunks Midstage Study, Pfizer To Invest In Arvinas, AbSci IPO Benzinga

08:18AM EDT Arvinas And Pfizer Announce Global Collaboration To Develop PROTAC Protein Degrader ARV-471 RTTNews

08:18AM EDT The Daily Biotech Pulse: FDA Nod For Merck-Eisai, Seres' Ulcerative Colitis Drug Flunks Midstage Study, Pfizer To Invest In Arvinas, AbSci IPO Benzinga

07:20AM EDT Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC Protein Degrader ARV-471; Arvinas To Receive $650M Upfront In Addition To A Potential $1.4B In Milestone Payments Benzinga

07:00AM EDT Collaboration combines Arvinas investigational estrogen receptor-targeting breast cancer therapy with Pfizers deep experience in breast oncology therapeutics GlobeNewswire Inc

Jun 22, 2021

02:24PM EDT Arvinas Shares See Large Block Trade: 1.3M Shares At $74.25; Stock Down ~5.5% For Session Benzinga

Jun 7, 2021

05:20PM EDT Arvinas Participates in Groundbreaking Ceremony for New Space GlobeNewswire Inc

Jun 3, 2021

07:00AM EDT Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ron Peck, M.D., Chief Medical Officer, and Sean Cassidy, Chief Financial Officer, will participate in a fireside chat at the 42nd Annual Goldman Sachs Global Healthcare Conference on Thursday, June 10 at 10:30 a.m. ET. GlobeNewswire Inc

May 21, 2021

10:08AM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 21, 2021 Benzinga

06:31AM EDT UBS Initiates Coverage On Arvinas with Buy Rating, Announces Price Target of $123 Benzinga

May 20, 2021

04:30PM EDT Arvinas to Present at the UBS Global Healthcare Virtual Conference GlobeNewswire Inc

May 4, 2021

02:52PM EDT Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it will be leasing three of the 10 floors at 101 College Street in New Haven, Conn. Winstanley Enterprises, LLC., is the developer on this multi-tenant project. GlobeNewswire Inc

07:35AM EDT Arvinas Sees Cash, Cash Equivalents, Marketable Securities Sufficient To Fund Its Planned Operating Expenses, Capex Into 2024 Benzinga

07:34AM EDT Arvinas Q1 Net Loss $41M vs $21.7M In Same Qtr. Last Year Benzinga

07:24AM EDT Arvinas Q1 Sales $5.5M, Down From $6.2M Benzinga

07:00AM EDT Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation, today reported financial results for the first quarter ended March 31, 2021 and provided a corporate update. GlobeNewswire Inc

Apr 21, 2021

01:59PM EDT Benzinga's Top Ratings Upgrades, Downgrades For April 21, 2021 Benzinga

07:56AM EDT Truist Securities Initiates Coverage On Arvinas with Buy Rating, Announces Price Target of $150 Benzinga

Apr 5, 2021

04:30PM EDT Arvinas Announces Upcoming Presentations at the American GlobeNewswire Inc

Mar 31, 2021

10:03AM EDT Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2021 Benzinga

06:32AM EDT BMO Capital Initiates Coverage On Arvinas with Outperform Rating, Announces Price Target of $101 Benzinga

Mar 10, 2021

04:30PM EST Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it will participate in two upcoming virtual investor conferences. John Houston, Ph.D., President and Chief Executive Officer, will participate in panel discussions at both conferences. GlobeNewswire Inc

Mar 1, 2021

07:59AM EST Arvinas: Q4 Earnings Insights Benzinga

07:19AM EST Arvinas Q4 EPS $(0.99) Misses $(0.78) Estimate, Sales $2.20M Miss $6.91M Estimate Benzinga

07:19AM EST Arvinas Q4 EPS $(0.99) Down From $(0.56) YoY, Sales $2.20M Down From $4.89M YoY Benzinga

07:00AM EST Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided a corporate update. GlobeNewswire Inc

Feb 8, 2021

04:30PM EST Arvinas to Present at the Guggenheim Healthcare Talks: 2021 GlobeNewswire Inc

Jan 31, 2021

04:32PM EST Notable Insider Buys In The Week Of Christmas: Foot Locker, GameStop, NetApp And More Benzinga

Jan 20, 2021

07:32AM EST The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study Benzinga

Jan 15, 2021

07:57AM EST The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges Benzinga

Jan 8, 2021

07:25AM EST The Daily Biotech Pulse: Sarepta Gene Therapy Study Readout, Novavax Vaccine Supply Deal, 2 IPOs Benzinga

Jan 5, 2021

08:39AM EST The Daily Biotech Pulse: Moderna Coronavirus Vaccine Receives Third Regulatory Nod, Gritstone Rallies On Hedge Fund Stake, aTyr's COVID-19 Drug Data Benzinga

Dec 29, 2020

08:09AM EST The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica Benzinga

Dec 28, 2020

04:30PM EST Arvinas, Inc. Announces Exercise of Underwriters GlobeNewswire Inc

Dec 26, 2020

01:53PM EST Notable Insider Buys In The Week Of Christmas: Foot Locker, GameStop, NetApp And More Benzinga

Dec 23, 2020

08:31AM EST The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut Benzinga

Dec 16, 2020

07:15AM EST The Daily Biotech Pulse: Novartis Gets Adcom Backing, Sio Gene Data, 2 IPOs, BioNTech Clinches China Vaccine Supply Deal Benzinga

06:49AM EST Arvinas Priced 5.71M Share Public Offering of Common Stock @$70/Share Benzinga

Dec 15, 2020

08:35PM EST Arvinas, Inc. Announces Pricing of $400 Million Public Offering of GlobeNewswire Inc

10:00AM EST Arvinas Shares Up 17%; Seeing Several Analyst Price Target Raises: Oppenheimer Raises From Outperform To Perform; Guggenheim Raises Price Target From $48 To $100; H.C. Wainwright Raises Price Target From $60 To $100 Benzinga

09:48AM EST ROCE Insights For Arvinas Benzinga

07:52AM EST The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding Benzinga

05:56AM EST A Peek Into The Markets: US Stock Futures Climb; Fed Meeting In Focus Benzinga

Dec 14, 2020

04:07PM EST Arvinas, Inc. Announces Proposed Offering of $250M of Common Stock Benzinga

04:07PM EST Arvinas, Inc. Announces Proposed Offering of Common Stock GlobeNewswire Inc

04:04PM EST Arvinas Filing Shows Registration For Mixed Securities Offering, No Size Disclosed Benzinga

02:33PM EST Mid-Afternoon Market Update: Dow Turns Negative; Arvinas Shares Spike Higher Benzinga

02:32PM EST Mid-Afternoon Market Update: Dow Turns Lower; Arvinas Shares Spike Higher Benzinga

12:08PM EST Mid-Day Market Update: Nasdaq Rises 1.1%; Aerpio Pharmaceuticals Shares Plummet Benzinga

11:08AM EST UPDATE: Goldman On Arvinas Says Raises Odds Of Success For Co.'s ARV-471 From 25% To 45% Following New Data Disclosed Monday Benzinga

10:14AM EST Mid-Morning Market Update: Markets Open Higher; FDA Authorizes Pfizer-BioNTech Covid-19 Vaccine Benzinga

10:00AM EST Shares of clinical-stage biopharmaceutical company Arvinas, Inc. (ARVN) are surging more than 95% Monday morning after the company announced positive interim clinical data of its PROTAC protein degraders ARV-471 and ARV-110. RTTNews

09:49AM EST Return On Capital Employed Overview: Arvinas Benzinga

07:38AM EST UPDATE: Arvnias Says ARV-471 Showed Evidence Of Anti-Tumor Activity, Co. Sees Initiation Of Combo Trial OF ARV-471 Plus Ibrance In December, Sees 3 Added Trials In Patients With Breast Cancer Beginning In 2021 Benzinga

07:13AM EST Arvinas Releases Interim Clinical Data Of PROTAC Protein Degraders ARV-471 And ARV-110 Benzinga

07:11AM EST Arvinas Releases Interim Clinical Data for its PROTAC Protein Degraders ARV-471 and ARV-110 Benzinga

07:00AM EST ARV-471 demonstrates evidence of anti-tumor activity, and potential for best-in-class safety, and estrogen receptor (ER) degradation profile and robust efficacy signals in a heavily pretreated patient population GlobeNewswire Inc

Dec 13, 2020

04:27PM EST The Week Ahead In Biotech: 2 IPOs Plus FDA Decisions On Moderna's COVID Vaccine And Drugs From Amgen, MacroGenics Benzinga

Dec 11, 2020

04:15PM EST Event to be webcast live on Monday, December 14, 2020 at 8:00 a.m. ET GlobeNewswire Inc

Nov 25, 2020

07:00AM EST Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming virtual investor conferences: GlobeNewswire Inc

Nov 5, 2020

07:30AM EST Arvinas Q3 EPS $(0.79) Down From $(0.54) YoY, Sales $7.60M Down From $30.05M YoY Benzinga

07:00AM EST Arvinas Reports Third Quarter 2020 Financial Results and Provides GlobeNewswire Inc

Oct 29, 2020

07:30AM EDT The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal Benzinga

Oct 14, 2020

07:13AM EDT Arvinas Announces Platform Updates, Disclose 5 Additional Programs From Preclinical Pipeline RTTNews

07:05AM EDT Arvinas Announces Pipeline Programs Targeting Validated and Classically "Undruggable" Disease-Causing Proteins Benzinga

07:01AM EDT Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced platform updates and disclosed five additional programs from its preclinical pipeline. Arvinas portfolio encompasses a range of validated and undruggable targets in oncology, immuno-oncology, and neuroscience. GlobeNewswire Inc

Oct 6, 2020

05:17PM EDT Arvinas to Present at the 3rd Annual Targeted Protein Degradation GlobeNewswire Inc

Sep 4, 2020

07:00AM EDT Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced thatIan Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the Citi 15th Annual BioPharma Virtual Conference onThursday, September 10at2:25 p.m. ET. GlobeNewswire Inc

Aug 7, 2020

07:00AM EDT Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced thatRon Peck, M.D., Chief Medical Officer, will participate in a fireside chat at the 2020 Wedbush PacGrow Virtual Healthcare Conference onTuesday, August 11at10:20 a.m. ET. GlobeNewswire Inc

Aug 4, 2020

07:19AM EDT Arvinas Q2 EPS $(0.65) Down From $(0.55) YoY, Sales $5.75M Up From $4.02M YoY Benzinga

07:00AM EDT Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation, today reported financial results for the second quarter ended June 30, 2020 and provided a corporate update. GlobeNewswire Inc

.dark-mode .fdRKq2{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .fdRKq2{ color: #333333; background-color: white; border: 2px solid #333333; }ARVNArvinas, Incstock NASDAQ

ARVN
Arvinas, Inc
stock NASDAQ